Contact this trialFirst, we need to learn more about you.
Anti-obesity Agent
Semaglutide for Atrial Fibrillation
Recruiting1 awardPhase 3
Phoenix, Arizona
"This trial aims to see how a weight loss medication called semaglutide, when combined with standard treatment for atrial fibrillation (AF), can impact AF severity and the risk of it coming back
Fill-in a few details and create your profileSave answers to your profile & unlock recommendations.
We will keep your details privateWe won't share unless you give us permission. By completing this form you agree to our privacy policy and terms of service.
Get in touch with the study teamWe’ll send your responses to the study team and help you to setup your first screening. This is not the start of informed consent. Screening happens between you and the trial.
By clicking start, you agree to our
terms of service